Cancer Drug Resistance: Targeting Proliferation or Programmed Cell Death.

cell death chemotherapy proliferation resistance

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
23 Feb 2024
Historique:
received: 10 01 2024
accepted: 19 02 2024
medline: 13 3 2024
pubmed: 13 3 2024
entrez: 13 3 2024
Statut: epublish

Résumé

The development of resistance to chemotherapy is one of the main problems for effective cancer treatment. Drug resistance may result from disturbances in two important physiological processes-cell proliferation and cell death. Importantly, both processes characterize alterations in cell metabolism, the level of which is often measured using MTT/MTS assays. To examine resistance to chemotherapy, different cancer cell lines are usually used for the in vitro modulation of developing resistance. However, after the creation of resistant cell lines, researchers often have difficulty in starting investigations of the mechanisms of insensitivity. In the first stage, researchers should address the question of whether the drug resistance results from a depression of cell proliferation or an inhibition of cell death. To simplify the choice of research strategy, we have suggested a combination of different approaches which reveal the actual mechanism. This combination includes rapid and high-throughput methods such as the MTS test, the LIVE/DEAD assay, real-time cell metabolic analysis, and Western blotting. To create chemoresistant tumor cells, we used four different cancer cell lines of various origins and utilized the most clinically relevant pulse-selection approach. Applying a set of methodological approaches, we demonstrated that three of them were more capable of modulating proliferation to avoid the cytostatic effects of anti-cancer drugs. At the same time, one of the studied cell lines developed resistance to cell death, overcoming the cytotoxic action.

Identifiants

pubmed: 38474352
pii: cells13050388
doi: 10.3390/cells13050388
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Russian Science Foundation
ID : 23-74-30006
Organisme : Swedish Cancer Society
ID : 222013
Organisme : Radium Hemmets Research Funds
ID : 181301

Auteurs

Elena V Sazonova (EV)

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Faculty of Medicine, MV Lomonosov Moscow State University, 119991 Moscow, Russia.

Maria A Yapryntseva (MA)

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Faculty of Medicine, MV Lomonosov Moscow State University, 119991 Moscow, Russia.

Nikolay V Pervushin (NV)

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Faculty of Medicine, MV Lomonosov Moscow State University, 119991 Moscow, Russia.

Roman I Tsvetcov (RI)

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Faculty of Medicine, MV Lomonosov Moscow State University, 119991 Moscow, Russia.

Boris Zhivotovsky (B)

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Faculty of Medicine, MV Lomonosov Moscow State University, 119991 Moscow, Russia.
Division of Toxicology, Institute of Environmental Medicine, Karolinska Institute, P.O. Box 210, 17177 Stockholm, Sweden.

Gelina S Kopeina (GS)

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Faculty of Medicine, MV Lomonosov Moscow State University, 119991 Moscow, Russia.

Classifications MeSH